Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07220564 · ClinicalTrials.gov registry record · Phase 1

A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A

A Phase 1 study of Haemophilia A, sponsored by Novo Nordisk A/S.

Recruiting
Registry status
Phase 1
Development phase
20
Enrollment target
18
Study locations

NCT07220564 is a Phase 1 study of Haemophilia A that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 20 participants, below the 223-participant average among 8 other Haemophilia A trials with a reported enrollment target (91% lower). The trial reports 18 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07220564, a Phase 1 study of Haemophilia A, is actively recruiting participants, sponsored by Novo Nordisk A/S.

RECRUITING
Registry status
Phase 1
Development phase
20 participants
Enrollment target
18
Study locations

Study Summary

This study will test how different doses of study medicine (Inno8) work in the bodies of people with haemophilia A. The purpose of the study is to see if Inno8 is safe to use for people with haemophilia A. The study medicine is a new medicine that cannot yet be prescribed by doctors. The study will last for about 11 weeks.

Conditions Studied

Haemophilia A

Interventions

  • DRUG NNC0442-0344 A

Study Locations (18)

Other

  • Universitätsklinik für Innere Medizin V - Innsbruck
  • AKH - Klin. Abt. f. Haematologie u. Haemostaseologie - Vienna
  • Vivantes Netzwerk für Gesundheit GmbH - Vivantes Klinikum im Friedrichshain - Berlin
  • Medizinische Hochschule Hannover - Hämatologie, Hämostaseologie, Onkologie - Hanover
  • AOU Careggi Firenze - Florence
  • Azienda Ospedaliera Universitaria Federico II di Napoli - Naples
  • Uniwersytecki Szpital Kliniczny w Bialymstoku - Bialystok
  • Uniwersyteckie Centrum Kliniczne - Gdansk
  • Instytut Hematologii i Transfuzjologii - Warsaw
  • Hospital Vall d'Hebron - Barcelona
  • Hospital Universitario La Paz - Madrid
  • Hospital Regional Universitario de Málaga - Málaga
  • Hospital Clinico Universitario de Salamanca - Salamanca
  • West Midlands Adult Comprehensive Care Haemophilia - Birmingham
  • Royal Free Hospital - Haemophilia - London

Indiana

  • Indiana Hemophilia-Thromb Ctr - Indianapolis

Iowa

  • University of Iowa_Iowa City - Iowa City

Pennsylvania

  • Penn State MS Hershey Med Ctr - Hershey

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-10-23
Est. Completion 2026-12-21
Phase Phase 1

Sponsor

Novo Nordisk A/S

431 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07220564

The ClinicalTrials.gov registry entry for NCT07220564 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 223-participant average among 8 other Haemophilia A trials with a reported enrollment target (91% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Haemophilia A appearing as the primary indexed condition, and to 1 intervention - of which NNC0442-0344 A is the first listed.

NCT07220564 reports 18 study locations spanning 4 distinct geographic areas - top geographies include Other, Indiana, Iowa.

Frequently Asked Questions

What is clinical trial NCT07220564 about?

NCT07220564 is a clinical study titled "A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A". This study will test how different doses of study medicine (Inno8) work in the bodies of people with haemophilia A. The purpose of the study is to see if Inno8 is safe to use for people with haemophilia A. The study medicine is a new medicine that cannot yet be prescribed by doctors. The study will ...

What is the current status of trial NCT07220564?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-10-23. Estimated completion is 2026-12-21.

What conditions does trial NCT07220564 study?

This clinical trial studies the following conditions: Haemophilia A.

What interventions are being tested in trial NCT07220564?

The interventions under investigation include: NNC0442-0344 A (DRUG).

Who is sponsoring clinical trial NCT07220564?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07220564 being conducted?

This trial has 18 study locations across Indiana, Iowa, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Haemophilia A

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Haemophilia A

All registered trials for this condition

Indiana

All trials with a study site in Indiana

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.